Deflazacort

Corticosteroid — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Deflazacort is an ofp drug in the Corticosteroid class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Corticosteroid Hormone Receptor Agonists. Recorded indications include Duchenne muscular dystrophy.

• Approval status: ofp (first approved 2017 by the FDA).
• Drug class: Corticosteroid.
• Mechanism of action: Corticosteroid Hormone Receptor Agonists.
• Indications: Duchenne muscular dystrophy.
• ATC code: H02AB13 (Glucocorticoids).
• Molecular formula: C25H31NO6; molecular weight 441.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Duchenne muscular dystrophy

Mechanism & targets

• Mechanism of action (MoA): Corticosteroid Hormone Receptor Agonists
• Established pharmacologic class: Corticosteroid

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2017-02-09	FDA	—	MARATHON PHARMACEUTICALS LLC	Yes

ATC classification

ATC code	Therapeutic hierarchy
H02AB13	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CORTICOSTEROIDS FOR SYSTEMIC USE › CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN › Glucocorticoids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
No adverse event	527.1
Weight increased	422.7
Product dose omission issue	337.9
Intentional dose omission	268.8
Abnormal behaviour	232.7
Increased appetite	201.0
Anger	181.9
Cushingoid	134.1
Influenza	134.0
Gastroenteritis viral	131.5
Mood altered	105.9
Emotional disorder	105.2

Chemical structure

• Molecular formula: C₂₅H₃₁NO₆
• Molecular weight: 441.52 g/mol
• CAS number: 14484-47-0
• InChIKey: FBHSPRKOSMHSIF-GRMWVWQJSA-N
• PubChem CID: 189821

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Deflazacort used for?

DrugCentral lists the following indications for Deflazacort: Duchenne muscular dystrophy.

How does Deflazacort work?

Deflazacort is classified as Corticosteroid Hormone Receptor Agonists.

When was Deflazacort first approved?

Deflazacort was first approved by the FDA in 2017.

What drug class does Deflazacort belong to?

Deflazacort is in the Corticosteroid class.

What is the chemical formula of Deflazacort?

Deflazacort has the molecular formula C25H31NO6 and a molecular weight of 441.52 g/mol.

Sources

• DrugCentral drug card 793 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201891 — compound record and bioactivity
• PubChem CID 189821 — chemical identifiers
• DrugBank DB11921 — drug record
• FDA UNII KR5YZ6AE4B — substance identity
• DailyMed: FDA labels for Deflazacort — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.